Royalty Pharma
Royalty Pharma plc, headquartered in the United States, is a leading player in the biopharmaceutical industry, specialising in the acquisition of revenue-generating pharmaceutical royalties. Founded in 1996, the company has established itself as a pioneer in the royalty financing model, enabling innovation in drug development while providing capital to biopharmaceutical companies. With a diverse portfolio that includes royalties from some of the world's most successful therapies, Royalty Pharma stands out for its unique approach to funding and supporting drug development. The company operates primarily in North America and Europe, positioning itself as a key partner in the life sciences sector. Notable achievements include a robust market presence and a commitment to advancing healthcare through strategic investments in transformative therapies.
DitchCarbon Score
How does Royalty Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Royalty Pharma's score of 35 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Royalty Pharma's reported carbon emissions
In 2024, Royalty Pharma reported significant carbon emissions, with Scope 3 emissions from investments amounting to approximately 23,266,000 kg CO2e. This figure represents a decrease from the previous year, 2023, when their Scope 3 emissions were about 32,002,000 kg CO2e. In 2022, the emissions were around 19,610,000 kg CO2e, indicating a fluctuating trend in their carbon footprint. For 2021, Royalty Pharma disclosed a total of 15,679,000 kg CO2e in Scope 1 emissions, 113,000 kg CO2e in Scope 2 emissions, and 5,000 kg CO2e in Scope 3 emissions, showcasing a more comprehensive reporting approach that year. However, the company has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. Overall, Royalty Pharma's emissions data highlights their reliance on Scope 3 emissions, particularly from investments, while their commitment to reducing carbon emissions remains unclear.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 15,679,000 | - | - | - |
| Scope 2 | 113,000 | - | - | - |
| Scope 3 | 5,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Royalty Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
